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Recently much attention has been directed toward kid-
ney protective property of erythropoietin (EPO) beyond
stimulating erythropoiesis. In the study conducted by
Moieni et al. the protective inpact of recombinant hu-
man erythropoietin in kidney and lung injury following
renal bilateral ischemia-reperfusion (I/R) in rat model
was investigated. They studied the role of EPO on renal
function makers and tissue damage as well as the lung
endothelial permeability in bilateral renal ischemia/re-
perfusion (I/R) injury model in rats [1]. In this study
they found that EPO protected the kidney against I/R in-
jury [1]. Likewise to this study, Ardalan et al. observed
that EPO pretreatment could also be effective in redu-
cing kidney and lung injury following kidney I/R and
could improve the cellular antioxidant defense system in
rat model. They concluded that EPO pretreatment might
be effective in attenuating renal and lung injuries after
renal I/R induced injury during surgical procedures,
hypotension, renal transplantation and other conditions
inducing renal I/R [2]. Similarly in a study on 40 male
Wistar rats, conducted to test the protective effect of
EPO on tubular cells, we observed that EPO was able to
attenuate an increase in serum creatinine and blood urea
nitrogen levels against gentamicin nephrotoxicity. More-
over, co-administration of gentamicin and EPO effectively
reduced renal tissue damage induced by gentamicin, com-
pared to the control group [3]. Our study disclosed the
renal protective effect of EPO, when the drug was adminis-
tered in combination with gentamicin [3-6]. Furthermore,
the ameliorative property of EPO was apparent even when
the drug was given after induction of kidney tubular dam-
age by gentamicin, and it was still applicable after tissue in-
jury [2-6]. Ameliorative effect of EPO against cisplatin
nephrotoxicity was shown in the study of Kong et al.
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reproduction in any medium, provided the orand exerting important anti-apoptotic properties [7].
Importantly, Rjiba-Touati et al. showed that EPO ad-
ministration especially in pretreatment situation pro-
tected rats against cisplatin-induced renal oxidative
stress and nephrotoxicity [8]. Similarly, the renopro-
tective effect of cisplatin-induced kidney damage was
shown in our previous study, too [9]. This indicates
that EPO may have curative impact, along with its pre-
ventive property [5-9]. Hence, EPO is a promising kid-
ney protective medication that can prevent, ameliorate,
or attenuate renal tubular damage induced by gentami-
cin or other injurious insults such as I/R [10-13]. Pre-
vious researches also showed the efficacy of EPO on
renal allograft survival, too [14-19]. In an experimental
study on six-week-old male rats, treated with cyclo-
sporine, Abe et al. found that carbamylated-EPO sup-
pressed macrophage infiltration, phenotypic alteration
of interstitial myofibroblasts and interstitial fibrosis in
the cyclosporine nephropathy model. They also found
that, carbamylated-EPO administration was able to de-
crease TGF-β1 mRNA level in cyclosporine -treated
kidney. In this study, tubular apoptosis was persistently
stimulated after cyclosporine treatment, while carba-
mylated erythropoietin significantly inhibited tubular
apoptosis. They concluded that carbamylated-EPO ad-
ministration was able to reduce cyclosporine -induced
tubule-interstitial injury in two ways by protection of
renal tubular epithelial cells from apoptosis and inhib-
ition of interstitial fibrosis [20]. Principally, EPO trig-
gers red blood cell maturation in bone marrow and
heightens erythropoiesis [17,19-23]. It is a glycoprotein
and a member of class I cytokines [1,17-19,24]. In fact
renal fibrosis is the final common event in all chronic
kidney disease (CKD) types with different etiologies.
Persistent inflammation and transition of pericytes to myo-
fibroblasts cause renal fibrosis and diminishing of erythro-
poietin production [17,19-23]. Recently, also some
investigators envisage administering the EPO therapy in
chronic kidney disease (CKD) prior to anemia, which will
benefit renal protective effectiveness of EPO in CKD [20].
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blasts from injured renal tubular epithelial cells have no sig-
nificant contribution in kidney fibrosis. However kidney
EPO-producing cells, originating from neural crests, differ-
entiate into myofibroblasts after a long time exposure to in-
flammation. It looks that they are involved in renal fibrosis
[19,22-26]. Macrophages and myofibroblasts are dominant
cells causing renal fibrosis. Macrophages can be differenti-
ated to phenotype M1 (classically activated) or M2 (wound
healing) regarding to the distinctive cytokine production
[19,22-26]. While, EPO can disconnect macrophages by
diminishing the activity of NF-κB, in vivo. Thus, macro-
phage regulation could be one of the mechanisms that ex-
plain the anti-fibrotic effect of EPO in CKD [19,22-26].
This may explain the missing link in CKD between renal fi-
brosis and anemia [19,22-24]. Some recent studies have in-
dicated the improvement of kidney function in CKD
following administration of EPO [19,22-26]. Thus it may be
reasonable to start erythropoietin prior to erythropoiesis in
CKD, too. Hence, to better understand the renoprotective
property of EPO, more experimental or clinical studies are
suggested.
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